<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:hpo ids='HP_0001427'>Mitochondrial</z:hpo> DNA (mtDNA) copy number is increased in patients with <z:hpo ids='HP_0005550'>chronic lymphocytic leukemia</z:hpo> (CLL), in Burkitt <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and Epstein-Barr virus-transformed lymphoblastoid cell lines, and in T cells activated via the T-cell receptor </plain></SENT>
<SENT sid="1" pm="."><plain>We hypothesized that having a higher mtDNA copy number in peripheral white blood cell DNA from healthy subjects would be associated with future risk of non-Hodgkin <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (NHL) </plain></SENT>
<SENT sid="2" pm="."><plain>We analyzed mtDNA copy number in 104 incident male NHL cases and 104 matched controls within the prospective <z:chebi fb="0" ids="22470">Alpha-Tocopherol</z:chebi>, <z:chebi fb="9" ids="17579">Beta-Carotene</z:chebi> (ATBC) <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">Cancer</z:e> Prevention cohort </plain></SENT>
<SENT sid="3" pm="."><plain>There was a dose-response relationship between tertiles of mtDNA copy number and risk of NHL (odds ratio [OR], 95% confidence interval [CI]: 1.0; 1.4 [0.7-2.8]; and 2.4 [1.0-5.5], respectively; P(trend) = .046) </plain></SENT>
<SENT sid="4" pm="."><plain>The effect was most pronounced for the CLL/small lymphocytic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">SLL</z:e>) subtype (OR: 1.0; 3.2 [0.7-15.7]; 14.1 [1.9-103.2]; P(trend) = .009) </plain></SENT>
<SENT sid="5" pm="."><plain>These results suggest that mtDNA copy number could be associated with the risk of NHL, particularly <z:e sem="disease" ids="C1302547" disease_type="Neoplastic Process" abbrv="">CLL/SLL</z:e> </plain></SENT>
</text></document>